Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

• Status: Terminated
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess whether peri-procedural administration of rectal indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dartmouth-Hitchcock Medical Center
• Treatments: Indomethacin

Criteria

Inclusion Criteria:

1. Scheduled for an ERCP at Dartmouth-Hitchcock

2. Age greater than 18 years old

3. Ability to provide written informed consent

Exclusion Criteria:

1. Inability to provide written informed consent

2. ERCP being performed for diagnosis and/or treatment of acute pancreatitis

3. Current ongoing acute pancreatitis

4. Previously documented allergy to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

5. Contra-indication to NSAID therapy (creatinine level >1.4 or active peptic ulcer disease), already taking NSAIDs (other than aspirin therapy for cardioprotection)

6. Pregnant or nursing mothers